Imaging endpoints for biologic therapy in chronic obstructive pulmonary disease

Area of Science:

• Pulmonology
• Immunology
• Radiology

Background:

• Chronic obstructive pulmonary disease (COPD) significantly impacts respiratory health, marked by exacerbations and progressive decline.
• A specific endotype of COPD involves type 2 inflammation, linked to increased exacerbations and treatment response.

Purpose of the Study:

• To explore the utility of imaging biomarkers for assessing disease modification in COPD patients treated with biologics.
• To evaluate if imaging measures can serve as effective clinical trial endpoints for COPD therapies.

Main Methods:

• Review of evidence from clinical trials, primarily in asthma, focusing on biologics targeting type 2 inflammation.
• Analysis of imaging parameters such as airway wall thickness, mucus plugging, and ventilation defect percentage.

Main Results:

• Biologics targeting type 2 inflammation show potential in reducing COPD exacerbations and improving lung function.
• Imaging measures including airway wall thickness and mucus plugging appear modifiable with biologic therapy.

Conclusions:

• Imaging endpoints offer a promising approach to evaluate disease modification and structural remodeling in COPD clinical trials.
• These endpoints may significantly reduce the sample size needed for trials investigating biologic therapies in COPD.